Safety and Tolerability of Duloxetine at 60 mg Once Daily in Elderly Patients With Major Depressive Disorder

Patients in the duloxetine group experienced a significant weight loss of -0.73 kg compared to -0.13 kg in the placebo group (P = 0.009).

• No deaths occurred during the study.
• Discontinuation rates due to adverse events were comparable between duloxetine (9.7%) and placebo (8.7%).
• Treatment-emergent dry mouth, nausea, and diarrhea were reported significantly more often with duloxetine compared to placebo.
• Changes in blood pressure and pulse were not significantly different between the two groups, except for a notable decrease in orthostatic systolic BP with duloxetine.
• The incidence of adverse events leading to discontinuation was not significantly different between the duloxetine and placebo groups.

AI simplified